Carisbamate vs Fosphenytoin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Carisbamate
Developed by SK Biopharmaceuticals Co., Ltd.
NCT00425282 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 study (study 1 of two identical trials) gave carisbamate 200 or 400 mg/day or placebo for 12 weeks to 565 adults with refractory partial-onset seizures. The registered primary endpoint was the change in partial-onset seizure frequency. The 400 mg/day dose met it (median reduction 27.27% vs 15.21% with placebo, P = 0.009, and the paper reports the responder rate was also significant at this dose), while 200 mg/day did not differ from placebo (P = 0.678). The primary endpoint was met at the higher dose and missed at the lower dose, so the result is mixed. Sources: EU Clinical Trials Register results (EudraCT 2006-003839-68) and Sperling et al., Epilepsia 2010.
Next expected readout: February 2027 · NCT05219617 (registry estimate)
Reported efficacy
The primary outcome is the change in seizure frequency of all simple partial motor, complex partial, or secondarily generalized seizures from the pretreatment baseline phase compared with the double-blind treatment phase.: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). (mixed)
Result source: NCT00425282
Fosphenytoin
Marketed by Pfizer
NCT01960075 · Phase 3 · completed
This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Carisbamate | Fosphenytoin |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00433667 | —Not posted · NCT00908453 |
| 50% responder rate | —Not posted · NCT00433667 | —Not posted · NCT00908453 |
| Seizure freedom | —Not posted · NCT00433667 | —Not posted · NCT00908453 |
Seizure frequency, % change
- Carisbamate
- —Not posted · NCT00433667
- Fosphenytoin
- —Not posted · NCT00908453
50% responder rate
- Carisbamate
- —Not posted · NCT00433667
- Fosphenytoin
- —Not posted · NCT00908453
Seizure freedom
- Carisbamate
- —Not posted · NCT00433667
- Fosphenytoin
- —Not posted · NCT00908453
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Carisbamate: 0 of 4 rows · Fosphenytoin: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fosphenytoin |
|---|---|
| Dropout rate | 38.2%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result22.2%400mg NCT01458522 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result400mg respiratory failure 6.7% acute respiratory failure 4.4% bradycardia 4.4% NCT01458522 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fosphenytoin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Fosphenytoin's landscape